Study results showed that maintenance high-dose ICS/LABA reduced the odds of a severe exacerbation by about 20% compared with medium-dose ICS/LABA. The absolute reduction in severe exacerbation risk with high-dose ICS/LABA is determined by patients’ exacerbation risk, and this effect size may be clinically relevant for patients if this risk is high.
Lung Sask in collaboration with RESPTREC® offers the Professional Education Portal as a method for respiratory educators and health care providers to enhance their professional learning with continuing education opportunities.
Over 6000+ more articles available in the Professional Education Portal.
Read articles and watch video presentations on the most recent research, position papers and guidelines. Track your CE time with the provided logbook.